Edwards Lifesciences (EW) Earnings Date & Reports
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease... Show more
EW is expected to report earnings to fall 4.63% to 74 cents per share on July 23
Edwards Lifesciences (EW) Q1 2026 Earnings Recap: Beats Estimates and Raises Full-Year Outlook
Key Takeaways
- Edwards Lifesciences reported Q1 sales of $1.65 billion, up 12.7% on a constant currency basis, surpassing consensus estimates of approximately $1.60 billion.
- Adjusted diluted earnings per share (EPS) came in at $0.78, beating the $0.73 consensus estimate.
- TAVR (transcatheter aortic valve replacement) sales grew 11.0% constant currency to $1.20 billion, while TMTT (Transcatheter Mitral and Tricuspid Therapies) surged 42.8% constant currency to $175 million.
- The company raised its full-year 2026 constant currency sales growth guidance to 9%-11% from 8%-10% and adjusted diluted EPS to $2.95-$3.05.
- Adjusted operating margin expanded to 31.4%, reflecting operational efficiency.
- Shares rose about 4% in after-hours trading following the results and upbeat guidance.
Earnings Context and Why It Matters
Edwards Lifesciences, a leader in structural heart technologies, released its first quarter results for the period ended March 31, 2026, amid a strategic focus following the divestiture of its Critical Care business. This earnings report is pivotal as it highlights progress in core franchises like TAVR and TMTT, which are driving long-term growth in the structural heart market. Investors are closely watching execution in these areas, given expanding indications for TAVR and emerging opportunities in mitral and tricuspid therapies. Strong results affirm the company's ability to innovate and capture market share in a competitive medtech landscape, influencing valuation amid broader healthcare sector dynamics.
Edwards Lifesciences delivered robust Q1 2026 results, with total sales reaching $1,648.6 million, a 16.7% increase on a reported basis and 12.7% constant currency from $1,412.7 million in the prior-year quarter. This topped consensus expectations of around $1.60 billion.
Adjusted diluted EPS was $0.78, up from $0.64 year-over-year and exceeding the $0.73 estimate, while GAAP diluted EPS from continuing operations rose to $0.66 from $0.62. Net income from continuing operations increased to $380.7 million.
Segment performance shone: TAVR sales hit $1,197.3 million (11.0% constant currency growth), TMTT reached $175.1 million (42.8% constant currency), and Surgical Structural Heart grew to $276.2 million (5.9% constant currency). Adjusted operating margin improved to 31.4% from 29.1%.
Guidance was raised, with full-year constant currency sales growth now at 9%-11% (total sales $6.5-$6.9 billion) and adjusted diluted EPS at $2.95-$3.05, reflecting confidence in TAVR (7%-9% growth) and TMTT ($740-$780 million).
AI Screener
Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore it today to enhance your investment strategy.
Market Reaction and Investor Sentiment
Following the Q1 earnings release on April 23, 2026, Edwards Lifesciences shares climbed approximately 4% in after-hours trading, reflecting positive investor response to the earnings beat, margin expansion, and raised full-year guidance. Sentiment appears optimistic, with emphasis on accelerating TMTT growth and TAVR durability, though some caution lingers around competitive pressures in structural heart.
Forward Outlook and Key Factors to Monitor
Edwards Lifesciences' raised 2026 guidance signals sustained momentum, with constant currency sales growth targeted at 9%-11% and adjusted EPS at $2.95-$3.05. TAVR remains the cornerstone, with 7%-9% growth expected amid broader indications like EARLY TAVR trials and potential CMS (Centers for Medicare & Medicaid Services) policy expansions.
TMTT's robust trajectory, guided to $740-$780 million, will be key, driven by launches like next-generation PASCAL and TRIFORMIS systems. Investors should track adoption rates, regulatory approvals (e.g., tricuspid expansions), and clinical data from ongoing trials such as PROGRESS.
Operational metrics like gross margins (78%-79%) and R&D spend (~17% of sales) warrant attention, alongside share repurchases ($1.5 billion remaining authorization). Broader risks include reimbursement changes, supply chain issues, and competition from peers. Quarterly updates on these will shape near-term sentiment.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Advertisement
General Information
a manufacturer of products to treat late-stage cardiovascular disease
Industry MedicalNursingServices